George Serafeim
Charles M. Williams Professor, Harvard Business School | Pioneer of ESG Strategy | Named One of the Most Influential People in ESG Investing by Barron's
2019 Nobel Laureate in Physiology or Medicine | Director of Clinical Research, Francis Crick Institute | Ludwig Institute, University of Oxford | Oxygen-Sensing Pioneer
Sir Peter Ratcliffe's Nobel Prize-winning discovery of how cells sense oxygen has produced approved drugs and reshaped cancer biology, anemia treatment, and cardiovascular research. As Director of Clinical Research at the Francis Crick Institute and a leading figure at Oxford, he carries rare scientific authority. Audiences gain a firsthand view of how decades of fundamental research become medicine that saves lives.
Want to book Sir Peter John Ratcliffe as a speaker for your event? Please provide the info below and we’ll get in touch within 24h:
Sir Peter Ratcliffe is a 2019 Nobel Laureate in Physiology or Medicine whose discovery of how cells detect and respond to oxygen has opened a new era in medicine. Nobel Prize speaker Sir Peter Ratcliffe serves as Director of Clinical Research at the Francis Crick Institute in London, a member of the Ludwig Institute for Cancer Research at the University of Oxford, and a Fellow of the Royal Society. His work has reshaped our understanding of fundamental biology and handed researchers a new set of molecular targets for treating cancer, anemia, cardiovascular disease, and other conditions driven by disordered oxygen sensing.
He is best known for elucidating the hypoxia-inducible factor (HIF) pathway, the system cells use to sense falling oxygen and trigger adaptive responses that include red blood cell production, metabolic reprogramming, and the growth of new blood vessels. Working in parallel with William Kaelin Jr. at Harvard and Gregg Semenza at Johns Hopkins, Ratcliffe showed how the oxygen-regulated breakdown of HIF-1α is controlled by prolyl hydroxylase enzymes, providing the mechanistic link between oxygen availability and gene expression. That discovery has already produced a new class of approved drugs, the HIF prolyl hydroxylase inhibitors now used to treat anemia in patients with chronic kidney disease.
Ratcliffe trained in medicine at Cambridge and Oxford before dedicating his career to a basic fact of biology: all complex life depends on oxygen, and cells must sense with precision when supply runs short. His laboratory, now based at the Crick and supported by a 2024 Wellcome award for New Horizons in Hypoxia Signalling, continues to probe how HIF is switched on and off and how tissues manage rapid oxygen stress. Beyond the Nobel, his honors include the Lasker Award (2016), the Gairdner International Award (2010), and the Sir Hans Krebs Medal. He was knighted for services to clinical medicine in 2014.
As a speaker, Sir Peter Ratcliffe offers an authoritative and deeply human account of how fundamental science drives medical progress. He speaks with clarity about the process of discovery, the patience and failed hypotheses behind a breakthrough, and the way basic biology becomes medicine that extends lives. For pharmaceutical companies, medical congresses, biotech investors, and academic institutions, this science speaker delivers a perspective that is intellectually galvanizing and practically relevant. Audiences leave with a deeper appreciation of what it means to pursue one question rigorously for decades, and what that commitment can ultimately deliver for patients worldwide.
The discovery of the HIF oxygen-sensing pathway ranks among the most consequential advances in modern biology. Ratcliffe follows the arc from a simple research question, how do cells detect low oxygen, to a molecular answer that has already yielded approved drugs and active development programs in oncology, anemia, and cardiovascular disease. A vivid account of how curiosity-driven science turns into clinical reality.
Drawing on his own career and the wider story of HIF-pathway drug development, Ratcliffe examines the path from laboratory insight to approved treatment, and what it reveals about the infrastructure, patience, and collaboration that translational research demands. Valuable for life sciences, pharma, and biotech audiences facing their own translational hurdles.
The oxygen-sensing pathway now touches conditions from tumor metastasis to ischemic heart disease to the biology of aging. Ratcliffe charts the frontier of hypoxia research and the therapeutic openings emerging from a deeper grasp of how cells and tissues handle oxygen stress, a forward-looking session for researchers, investors, and strategic leaders in the life sciences.
A reflective, personal keynote on what it takes to pursue one scientific question for decades, absorb setbacks, and finally reach a result that changes medicine. Ratcliffe speaks candidly about the culture of research institutions, the place of failure in discovery, and what academic and corporate R&D leaders can learn from the long game of fundamental science.
| Basic Data Protection Information | |
|---|---|
| Data controller | AURUM SPEAKERS BUREAU S.L. |
| Address | Parc Audiovisual de Catalunya 1, Oficina S11, 08225 Terrassa, Spain |
| Purposes | We will use your data to respond to your requests and deliver our services to you. |
| Marketing | We will only send you marketing correspondence if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Lawful basis | We will only process your data if you have given your prior consent, which you can do by ticking the box for that purpose. |
| Recipients | Generally, only our members of staff who have been duly authorised may access the data that you have provided. |
| Your Rights | You have the right to know what information we hold about you, to rectify it and to erase it, as explained in the additional information available on our website. |
| Additional Information | For more information, please see our "PRIVACY POLICY". |